nach oben

19.02.2024

Antiviral Mechanism and Clinical Benefits of Mouthwash Active Against SARS-CoV-2

verfasst von: Verônica Caroline Brito Reia, Bernardo da Fonseca Orcina, Fabiano Vieira Vilhena, Paulo Sérgio da Silva Santos

Erschienen in: Current Oral Health Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We aim to review the spectrum of biological mechanisms of mouthwashes shown to be active against SARS-CoV-2, evidence for efficacy in reduction of viral load, in vitro and in vivo, and the potential for clinical benefit in use of mouthwashes in the context of COVID-19.

Recent Findings

Numerous studies have now been performed to establish the antiviral efficacy of specific mouthwash ingredients against SARS-CoV-2. A combination of biological in vitro studies and clinical studies which assess reduction of viral load in vivo have been performed. Certain mouthwash ingredients have been shown to have anti-SARS-CoV-2 effect, both in vitro and in vivo, for example, by reducing viral load detectable in saliva during acute COVID-19 infection. In addition, iron phthalocyanine, which has antibacterial, antifungal, and antiviral properties, has been tested using in vitro tests, cross-sectional population studies, and randomized clinical trials to assess clinical benefit of its use in the context of hospitalized patients with COVID-19.

Summary

A non-systematic search of the literature was conducted to find studies which generally investigated the mechanisms of action of specific mouthwash ingredients including chlorhexidine (CHX), cetylpyridinium chloride (CPC), ethyl lauroyl arginate (ELA), hydrogen peroxide (HP), povidone-iodine (PVP-I), and anionic phthalocyanine derivative (APD). The terms “Coronavirus infections,” “Severe Acute Respiratory Syndrome Coronavirus 2,” “In vitro techniques,” “Mouthwash,” and “Dentifrices” were used to search the electronic databases. Included were full-text articles in Portuguese, English, and Spanish that could be read online without limitations on the publication year. In clinical investigations, CPC has been demonstrated to lower SARS-CoV-2 viral load in saliva for up to 6 h, chlorhexidine was shown to reduce viral load for 60 min, and PVP-I 1% showed the ability to decrease SARS-CoV-2 for up to 3 h. Mouthwash containing APD has shown potential for benefit in clinical application as an adjunct to standard care in the setting of acute COVID-19. This mouthwash ingredient has shown evidence for reducing symptoms, length of hospital admission, need for intensive care admission, and mortality.

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052.CrossRefPubMedPubMedCentral

Zhong M, Lin B, Pathak JL, et al. ACE2 and furin expressions in oral epithelial cells possibly facilitate COVID-19 infection via respiratory and fecal-oral routes. Front Med (Lausanne). 2020;7:580796. https://doi.org/10.3389/fmed.2020.580796.CrossRefPubMed

Chen L, Zhao J, Peng J, et al. Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients. Cell Prolif. 2020;53(12):e12923. https://doi.org/10.1111/cpr.12923.CrossRefPubMedPubMedCentral

Huang N, Pérez P, Kato T, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2020;27(5):892–903. https://doi.org/10.1038/s41591-021-01296-8.CrossRef

Matuck BF, Dolhnikoff M, Maia GV, et al. Periodontal tissues are targets for Sars-Cov-2: a post-mortem study. J Oral Microbiol. 2020;13(1):1848135. https://doi.org/10.1080/20002297.2020.1848135.CrossRef

Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary glands: potential reservoirs for COVID-19 asymptomatic infection. J Dent Res. 2020;99(8):989. https://doi.org/10.1177/0022034520918518.CrossRefPubMed

Matuck BF, Dolhnikoff M, Duarte-Neto AN, et al. Salivary glands are a target for SARS-CoV-2: a source for saliva contamination. J Pathol. 2021;254(3):239–43. https://doi.org/10.1002/path.5679.CrossRefPubMedPubMedCentral

Carrouel F, Conte MP, Fisher J, Gonçalves LS, Dussart C, Llodra JC, Bourgeois D. COVID-19: a recommendation to examine the effect of mouthrinses with β-cyclodextrin combined with citrox in preventing infection and progression. J Clin Med. 2020;9(4):1126. https://doi.org/10.3390/jcm9041126.CrossRefPubMedPubMedCentral

Proverbio ZE, Bardavid SM, Arancibia EL, Schulz PC. Hydrophile–lipophile balance and solubility parameter of cationic surfactants. Colloids Surfaces A: Physicochem Eng Asp. 2003;214:167–71. https://doi.org/10.1016/S0927-7757(02)00404-1.CrossRef

10.

D’Amico F, Moro M, Saracino M, Marmiere M, Cilona MB, Lloyd-Jones G, Zangrillo A. Efficacy of cetylpyridinium chloride mouthwash against SARS-CoV-2: a systematic review of randomized controlled trials. Mol Oral Microbiol. 2023;38(3):171–80. https://doi.org/10.1111/omi.12408.CrossRefPubMed

11.

Saud Z, Tyrrell VJ, Zaragkoulias A, Protty MB, Statkute E, Rubina A, et al. The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses. J Lipid Res. 2022;63(6):100208. https://doi.org/10.1016/j.jlr.2022.100208.CrossRefPubMedPubMedCentral

12.

Okamoto N, Saito A, Okabayashi T, Komine A. Virucidal activity and mechanism of action of cetylpyridinium chloride against SARS-CoV-2. J Oral Maxillofac Surg Med Pathol. 2022;34(6):800–4. https://doi.org/10.1016/j.ajoms.2022.04.001.CrossRefPubMedPubMedCentral

13.

Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D, Ng DHL, et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2021;49(2):305–11. https://doi.org/10.1007/s15010-020-01563-9.CrossRefPubMed

14.

Moosavi MS, Aminishakib P, Ansari M. Antiviral mouthwashes: possible benefit for COVID-19 with evidence-based approach. J Oral Microbiol. 2020;12(1):1794363. https://doi.org/10.1080/20002297.2020.1794363.CrossRefPubMedPubMedCentral

15.

Testori T, Wang HL, Basso M, Bordini G, Dian A, Vitelli C, Miletic I, Del Fabbro M. COVID-19 and oral surgery: a narrative review of preoperative mouth rinses. Acta Stomatol Croat. 2020;54(4):431–41. https://doi.org/10.15644/asc54/4/10.CrossRefPubMedPubMedCentral

16.

Reis INR, do Amaral GCLS, das Mendoza AAH, Graças YT, Mendes-Correa MC, Romito GA, Pannuti CM. Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols? Med Hypotheses. 2021;146:110436. https://doi.org/10.1016/j.mehy.2020.110436.CrossRefPubMed

17.

Bernstein D, Schiff G, Echler G, Prince A, Feller M, Briner W. In vitro virucidal effectiveness of a 0.12%-chlorhexidine gluconate mouthrinse. J Dent Res. 1990;69(3):874–6. https://doi.org/10.1177/00220345900690030901.CrossRefPubMed

18.

Yoon JG, Yoon J, Song JY, Yoon SY, Lim CS, Seong H, Noh JY, Cheong HJ, Kim WJ. Clinical significance of a high SARS-CoV-2 viral load in the saliva. J Korean Med Sci. 2020;35(20):e195. https://doi.org/10.3346/jkms.2020.35.e195.CrossRefPubMedPubMedCentral

19.

Eduardo FP, Corrêa L, Heller D, Daep CA, Benitez C, Malheiros Z, Stewart B, Ryan M, Machado CM, Hamerschlak N, Rebello Pinho JR, Bezinelli LM. Salivary SARS-CoV-2 load reduction with mouthwash use: a randomized pilot clinical trial. Heliyon. 2021;7(6):e07346. https://doi.org/10.1016/j.heliyon.2021.e07346.CrossRefPubMedPubMedCentral

20.

Aznar M, Gómez-Estaca J, Vélez D, Devesa D, Nerín C. Migrants determination and bioaccessibility study of ethyl lauroyl arginate (LAE) from a LAE-based antimicrobial food packaging material. Food Chem Toxicol. 2013;56:363–70. https://doi.org/10.1016/j.fct.2013.02.018.CrossRefPubMed

21.

Gallob JT, Lynch M, Charles C, Ricci-Nittel D, Mordas C, Gambogi R, Revankar R, Mutti B, Labella R. A randomized trial of ethyl lauroyl arginate-containing mouthrinse in the control of gingivitis. J Clin Periodontol. 2015;42(8):740–7. https://doi.org/10.1111/jcpe.12428.CrossRefPubMedPubMedCentral

22.

O’Donnell VB, Thomas D, Stanton R, Maillard JY, Murphy RC, Jones SA, et al. Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function (Oxf). 2020;1(1):zqaa002. https://doi.org/10.1093/function/zqaa002.

23.

Dev Kumar G, Mishra A, Dunn L, Townsend A, Oguadinma IC, Bright KR, Gerba CP. Biocides and novel antimicrobial agents for the mitigation of coronaviruses. Front Microbiol. 2020;11:1351. https://doi.org/10.3389/fmicb.2020.01351.CrossRefPubMedPubMedCentral

24.

Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020;12(1):9. https://doi.org/10.1038/s41368-020-0075-9.CrossRefPubMedPubMedCentral

25.

Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Comparison of in vitro inactivation of SARS CoV-2 with hydrogen peroxide and povidone-iodine oral antiseptic rinses. J Prosthodont. 2020;29(7):599–603. https://doi.org/10.1111/jopr.13220.CrossRefPubMedPubMedCentral

26.

Gottsauner MJ, Michaelides I, Schmidt B, Scholz KJ, Buchalla W, Widbiller M, Hitzenbichler F, Ettl T, Reichert TE, Bohr C, Vielsmeier V, Cieplik F. A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. Clin Oral Investig. 2020;24(10):3707–13. https://doi.org/10.1007/s00784-020-03549-1.CrossRefPubMedPubMedCentral

27.

Encinar JA, Menendez JA. Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2′-O-methylation of viral RNA. Viruses. 2020;12(5):525. https://doi.org/10.3390/v12050525.CrossRefPubMedPubMedCentral

28.

Sharshov K, Solomatina M, Kurskaya O, Kovalenko I, Kholina E, Fedorov V, Meerovich G, Rubin A, Strakhovskaya M. The photosensitizer octakis(cholinyl)zinc phthalocyanine with ability to bind to a model spike protein leads to a loss of SARS-CoV-2 infectivity in vitro when exposed to far-red LED. Viruses. 2021;13(4):643. https://doi.org/10.3390/v13040643.

29.

Sadraeian M, Zhang L, Aavani F, Biazar E, Jin D. Photodynamic viral inactivation assisted by photosensitizers. Mater Today Phys. 2022;(28). https://doi.org/10.1016/j.mtphys.2022.100882.

30.

•• Santos C, da Fonseca Orcina B, Brito Reia VC, et al. Virucidal activity of the antiseptic mouthwash and dental gel containing anionic phthalocyanine derivative: In vitro study. Clin Cosmet Investig Dent. 2021;13:269–74. https://doi.org/10.2147/CCIDE.S315419. An in vitro study revealed that APD mouthwash and dental gel reduced the viability of the SARS-CoV-2 virus particles.

31.

Vilhena FV, Brito Reia VC, da Fonseca Orcina B, et al. The use of antiviral Phthalocyanine mouthwash as a preventive measure against COVID-19. GMS Hyg Infect Control. 2021;16:Doc24. https://doi.org/10.3205/dgkh000395.

32.

Orcina BDF, Reia VCB, Santos CA, et al. Atividade antibacteriana e antifúngica de produtos intraorais contendo ftalocianina: estudo in vitro. Praça de Pesquisa; 2021. https://doi.org/10.21203/rs.3.rs-1097185/v1.

33.

Organização Mundial da Saúde. Gestão clínica da COVID-19: orientação provisória, 27 de maio de 2020. Organização Mundial da Saúde. 2020. https://iris.who.int/handle/10665/332196.

34.

da Fonseca Orcina B, Vilhena FV, Cardoso de Oliveira R, Marques da Costa Alves L, Araki K, Toma SH, et al. A phthalocyanine derivate mouthwash to gargling/rinsing as an option to reduce clinical symptoms of COVID-19: Case Series. Clin Cosmet Investig Dent. 2021;13:47–50. https://doi.org/10.2147/CCIDE.S295423.

35.

da Fonseca Orcina B, Santos PSS. Oral manifestation COVID-19 and the rapid resolution of symptoms post-phtalox treatment: a case series. Int J Odontostomat. 2021;15(1):67–70.CrossRef

36.

Centers for Disease Control and Prevention (CDC) SARS-CoV-2 variant classifications and definitions. Atlanta: CDC. 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants.

37.

•• Vilhena FV, da Fonseca Orcina B, Lemos L, Less JCF, Pinto I, da Silva Santos PS. Elimination of SARS-CoV-2 in nasopharynx and oropharynx after use of an adjuvant gargling and rinsing protocol with an antiseptic mouthwash. Einstein (São Paulo). 2022;19:eCE6999. https://doi.org/10.31744/einstein_journal/2021CE6999. Use of phthalocyanine derivative mouthwash caused the elimination of the SARS-CoV-2 virus in different strains.

38.

• Reia VCB, Bastos RS, Vilhena FV, et al. Population-based virucidal phthalocyanine gargle/rinse protocol to reduce the risk of coronavirus disease-2019: a community trial. Res Sq [Preprint]. 2021. https://doi.org/10.21203/rs.3.rs-1065834/v1. The use of the APD mouthwash protocol appears to lower the population-level incidence of COVID-19.

39.

•• da Silva Santos PS, da Fonseca Orcina B, Machado RRG, Vilhena FV, da Costa Alves LM, Zangrando MSR, et al. Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial. Sci Rep. 2021;11(1):19937. https://doi.org/10.1038/s41598-021-99013-5. Using mouthwashes with a substance that has antiviral effects against the SARS-CoV-2 virus, according to a randomized clinical trial, can reduce patients' symptoms and the spread of infection.

40.

Poleti ML, Gregório D, Bistaffa AGI, et al. The use of a mouthwash and a dentifrice containing antimicrobial phthalocyanine derivative on the reduction of clinical symptoms of COVID-19: a randomized triple-blinded clinical trial. Res Sq [Preprint]. 2021. https://doi.org/10.21203/rs.3.rs-1139111/v1.

41.

Kawana R, Kitamura T, Nakagomi O, Matsumoto I, Arita M, Yoshihara N, Yanagi K, Yamada A, Morita O, Yoshida Y, Furuya Y, Chiba S. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. Dermatology. 1997;195(2):29–35. https://doi.org/10.1159/000246027.CrossRefPubMed

42.

Nagatake T, Ahmed K, Oishi K. Prevention of respiratory infections by povidone-iodine gargle. Dermatology. 2002;204(1):32–6. https://doi.org/10.1159/000057722.CrossRefPubMed

43.

Anderson DE, Sivalingam V, Kang AEZ, Ananthanarayanan A, Arumugam H, Jenkins TM, Hadjiat Y, Eggers M. Povidone-iodine demonstrates rapid in vitro virucidal activity against SARS-CoV-2, the virus causing COVID-19 disease. Infect Dis Ther. 2020;9(3):669–75. https://doi.org/10.1007/s40121-020-00316-3.CrossRefPubMedPubMedCentral

44.

Hassandarvish P, Tiong V, Sazaly AB, Mohamed NA, Arumugam H, Ananthanarayanan A, Qasuri M, Hadjiat Y. Povidone iodine gargle and mouthwash. Br Dent J. 2020;228(12):900. https://doi.org/10.1038/s41415-020-1794-1.CrossRefPubMedPubMedCentral

45.

Martinez Lamas L, Diz Dios P, Perez Rodriguez MT, Del Campo P, Cabrera Alvargonzalez JJ, Lopez Dominguez AM, Fernandez Feijoo J, Diniz Freitas M, Limeres Posse J. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. 2020. [epub ahead of print 2 Jul 2020]. https://doi.org/10.1111/odi.13526.

46.

Mao X, Auer DL, Buchalla W, Hiller KA, Maisch T, Hellwig E, Al-Ahmad A, Cieplik F. Cetylpyridinium chloride: mechanism of action, antimicrobial efficacy in biofilms, and potential risks of resistance. Antimicrob Agents Chemother. 2020;64(8):e00576-e620. https://doi.org/10.1128/AAC.00576-20.CrossRefPubMedPubMedCentral

47.

Meng L, Hua F, Bian Z. Coronavirus disease 2019 (COVID-19): emerging and future challenges for dental and oral medicine. J Dent Res. 2020;99(5):481–7. https://doi.org/10.1177/0022034520914246.CrossRefPubMed

48.

Van Swaaij BWM, van der Weijden GAF, Bakker EWP, Graziani F, Slot DE. Does chlorhexidine mouthwash, with an anti-discoloration system, reduce tooth surface discoloration without losing its efficacy? A systematic review and meta-analysis. Int J Dent Hyg. 2020;18(1):27–43. https://doi.org/10.1111/idh.12402.CrossRefPubMed

49.

How Does COVIXYL-V Nasal Spray Work? Available online: https://salvacion-usa.com/facts-about-salvacions-product. Accessed 14 Jun 2023.

50.

Pilicheva B, Boyuklieva R. Can the nasal cavity help tackle COVID-19? Pharmaceutics. 2021;13(10):1612. https://doi.org/10.3390/pharmaceutics13101612.CrossRefPubMedPubMedCentral

Titel: Antiviral Mechanism and Clinical Benefits of Mouthwash Active Against SARS-CoV-2
verfasst von: Verônica Caroline Brito Reia
Bernardo da Fonseca Orcina
Fabiano Vieira Vilhena
Paulo Sérgio da Silva Santos
Publikationsdatum: 19.02.2024
Verlag: Springer International Publishing
Erschienen in: Current Oral Health Reports
Elektronische ISSN: 2196-3002
DOI: https://doi.org/10.1007/s40496-024-00368-1

Neu im Fachgebiet Zahnmedizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

19.04.2024 Vorhofflimmern Nachrichten

Werden Personen mit Vorhofflimmern in der Blanking-Periode nach einer Katheterablation gegen eine bestehende Parodontitis behandelt, verbessert dies die Erfolgsaussichten. Dafür sprechen die Resultate einer prospektiven Untersuchung.

Invasive Zahnbehandlung: Wann eine Antibiotikaprophylaxe vor infektiöser Endokarditis schützt

11.04.2024 Endokarditis Nachrichten

Bei welchen Personen eine Antibiotikaprophylaxe zur Prävention einer infektiösen Endokarditis nach invasiven zahnärztlichen Eingriffen sinnvoll ist, wird diskutiert. Neue Daten stehen im Einklang mit den europäischen Leitlinienempfehlungen.

Zell-Organisatoren unter Druck: Mechanismen des embryonalen Zahnwachstums aufgedeckt

08.04.2024 Zahnmedizin Nachrichten

Der Aufbau von Geweben und Organen während der Embryonalentwicklung wird von den Zellen bemerkenswert choreografiert. Für diesen Prozess braucht es spezielle sogenannte „Organisatoren“. In einer aktuellen Veröffentlichung im Fachjournal Nature Cell Biology berichten Forschende durch welchen Vorgang diese Organisatoren im Gewebe entstehen und wie sie dann die Bildung von Zähnen orchestrieren.

Die Oralprophylaxe & Kinderzahnheilkunde umbenannt

11.03.2024 Kinderzahnmedizin Nachrichten

Infolge der Umbenennung der Deutschen Gesellschaft für Kinderzahnheilkunde in Deutsche Gesellschaft für Kinderzahnmedizin (DGKiZ) wird deren Mitgliederzeitschrift Oralprophylaxe & Kinderzahnheilkunde in Oralprophylaxe & Kinderzahnmedizin umbenannt. Aus diesem Grunde trägt die erste Ausgabe in 2024 erstmalig den neuen Titel.

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen